Drugs / Daxdilimab
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04526912 | Aug 2020 → Apr 2021 | acute lung injury | Viela Bio | Terminated | No outcome recorded |
| Phase 1 | NCT03817424 | Dec 2018 → Jul 2020 | Sjogren syndrome, cutaneous lupus erythematosus, dermatomyositis, systemic lupus erythematosus +1 | Amgen | Completed | No outcome recorded |
| Phase 26 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT05669014 | Dec 2023 → Jul 2025 | idiopathic inflammatory myopathy | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT05540665 | Apr 2023 → Jan 2024 | lupus nephritis | Amgen | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05591222 | Dec 2022 → May 2025 | discoid lupus erythematosus | Amgen | Terminated | Met primary Stop: Business |
| Phase 2 | NCT05430854 | Jun 2022 → Oct 2023 | systemic lupus erythematosus | Amgen | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05368103 | Apr 2022 → Aug 2023 | alopecia areata | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT04925934 | May 2021 → May 2023 | systemic lupus erythematosus | Amgen | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02780674 Comparator | Aug 2016 → Oct 2017 | dermatomyositis, systemic lupus erythematosus, systemic sclerosis | Amgen | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-07-07 | SBI Biotech Co., Ltd. | SBIバイオテックが導出した抗ILT7抗体（HZN-7734）の第Ⅱ相臨床試験における開発マイルストーン達成のお知らせ sbibiotech.jp ↗ |
| 2016-10-21 | SBI Biotech Co., Ltd. | SBIバイオテックが導出した抗ILT7抗体（MEDI7734）の第Ⅰ相臨床試験における開発マイルストーン達成のお知らせ sbibiotech.jp ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Daxdilimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05669014 ↗ |
| Known as | HZN-7734 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594330 ↗ |
| Known as | MEDI7734 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02780674 ↗ |
| Known as | VIB7734 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04925934 ↗ |
| Action | Deplete | “causes temporary depletion of plasmacytoid dendritic cells (pDCs)” NCT02780674 ↗ |
| Action | Inhibit | “Leukocyte immunoglobulin-like receptor subfamily A member 4 inhibitor” CHEMBL4594330 ↗ |
| Modality | Monoclonal antibody | “MEDI7734 is a human monoclonal antibody” NCT02780674 ↗ |
| Route | Subcutaneous | “administered as a subcutaneous (under the skin) injection.” NCT02780674 ↗ |
| Target | LILRA4 | “Leukocyte immunoglobulin-like receptor subfamily A member 4 inhibitor” CHEMBL4594330 ↗ |